Workshop to Identify Critical Windows of Exposure for Children’s Health: Cardiovascular and Endocrine Work Group Summary

Mason Barr Jr.,1 John M. DeSesso,2 Christopher S. Lau,3 Clive Osmond,4 Susan E. Ozanne,5 Thomas W. Sadler,6 Rebecca A. Simmons,7 and Babsaheb R. Sonawane8

1Departments of Pediatrics, Pathology and Obstetrics, University of Michigan, Ann Arbor, Michigan, USA; 2MITREtek Systems, McLean, Virginia, USA; 3National Health and Environment Effects Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA; 4Medical Research Council, Environmental Epidemiology Unit, Southhampton General Hospital, Southampton, United Kingdom; 5Department of Clinical Biochemistry, Addenbrooke’s Hospital, Cambridge, United Kingdom; 6UNC Birth Defects Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 7Division of Neonatology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; 8Effects Identification and Characterization Group, National Center for Environmental Assessment, U.S. Environmental Protection Agency, Washington, D.C., USA

The work group on cardiovascular and endocrine effects was asked to review the current state of knowledge about children’s windows of vulnerability to developmental toxicants and to recommend how that information may be used to improve risk assessment and public health. We considered differences between structural defects, where periods of vulnerability are rather well defined, and functional defects, where periods of vulnerability are quite elusive. Key words: developmental toxicity, endocrine, heart, teratogen. — Environ Health Perspect 108(suppl 3):569–571 (2000).
http://ehpnet1.niehs.nih.gov/docs/2000/suppl-3/569-571barr/abstract.html

The work group on cardiovascular and endocrine effects reviewed the current state of knowledge about children’s windows of vulnerability to developmental toxicants and made recommendations for how that information may be used to improve risk assessment and public health. The three background papers by Hoet and Reusens (1), Osmond (2), and Sadler (3) form an essential base for our ensuing discussions, and little of the information in those articles will be reiterated here. We cite only a few references in support of particular points.

There are windows of vulnerability for structural alterations; whereas the inception of vulnerability is often poorly defined, the end of vulnerability is usually well defined. The principal reason for uncertainty about the initiation of the vulnerable period is that cascades of gene action and development exist, but their sequences and timing are not yet fully worked out. The closer we look, the more evident it is that often there is not a uniform response within a given “window.” There may be peaks and valleys, or various slopes of sensitivity, within the period of vulnerability. Although there is increased recognition of the role of regulatory genes and gene cascades, its also evident that the same gene has different roles and timing in different tissues.

We believe that the question of who might be susceptible to teratogenesis is largely determined by the genome. Genomic influence on the expression of teratogenesis has been repeatedly reported in laboratory animals (4), and at least one recent study notes the interaction between a teratogen and a specific gene in the mouse (5). There is anecdotal evidence that teratogen–gene interaction occurs in humans as well (6,7). Drugs and genes may not only intrac, but one may mimic the other [e.g., sonic hedgehog and retinoids (8)]. In the future, epidemiological and genetic study combined may identify subgroups of children who are more vulnerable through environment–genome interaction.

For humans, the definition of windows of vulnerability for functional aberrations is more elusive than for structural anomalies. Currently, windows of vulnerability are considered the period of liability that extends from at least the second trimester of gestation, and probably the first trimester, onward. Preconceptional liability remains more speculative.

The term “developmental toxicant” is used rather loosely to encompass true teratogens, embryotoxins, and fetotoxins. Recognized human teratogens cause rather specific syndromes, although it is possible that environmental agents may also act to interfere with development in such a way as to produce single malformations or particular functional deficits. For prenatal exposure, we restricted our consideration to maternal exposure; paternally mediated, environmental effects were considered substantiated. It was noted that additive or synergistic exposure effects are largely unexplored, particularly in humans. There is abundant evidence that nutrition plays a key role in the etiology and prevention of birth defects and in the subsequent health of an individual. In the case of the conceptus, the route and dynamics of nutrition change during gestation. Initially by simple diffusion, nutrition is then controlled by the yolk sac (in the rodent) and ultimately by the chorionallantoic placenta.

Cardiovascular

We distinguished between structure and function in the cardiovascular system. In this system, a structurally abnormal heart may have abnormal function. For this system, “functional abnormality” refers more specifically to aberrant function or disease of the structurally normal heart.

Cardiovascular Structure

Each particular defect will have its own critical window of vulnerability. As the details of cardiogenesis become better understood, these periods of vulnerability will be better defined. Further investigation in this area should be supported. More information on possible environmental interactions with gene cascades in cardiogenesis would enhance our ability to detect potential teratogens.

However, we believe there is already enough known about cardiovascular development that it is no longer tenable to lump heart defects together as though they were a single entity. Rather they should be considered individual defects or mechanistically related groups of defects (8). As for the particular mechanisms involved in cardiogenesis, neural crest migration, endocardial cushion development, and mesenchymal–myocardial transformation would seem to be the most important areas on which to concentrate. Alterations of hemodynamics may affect structural cardiovascular development, but associating this with environmental exposure is uncertain. In distinction to other organs such as the brain, apoptosis appears to have a very limited role in normal cardiogenesis (only in the atrial septum). An appropriate
strategy for epidemiological study would focus on the most common structural lesions as individual entities. The detection of rare lesions associated with rare exposures (e.g., lithium and Ebstein malformation) could be left to the “alert practitioner.”

Epidemiological studies to date have largely failed to verify environmental agents as causes of cardiac defects, but they have raised some question about particular exposures and particular defects (9). Several past surveys have encountered problems with sample size, misclassification of exposure, and inappropriate grouping of outcomes. More refined data on actual timing of exposure would be helpful in determining any cause–effect relationships for specific defects. For example, the recurring controversy over a putative link between steroid exposure and cardiac malformation might be resolved by more precise information on the timing of exposure. Nonetheless, we recommend not narrowing the current definition of the window of vulnerability to cardiac malformation (fertilization to 8 weeks, most lesions at 3–5 weeks).

We recommend that patent ductus arteriosus (PDA) should be treated separately from true structural defects of the heart and great vessels. Because prostaglandin inhibition affects ductal closure, we think that PDA is better viewed as a functional defect.

Current protocols, for both laboratory animal and human investigation, largely miss what we believe is important information. Standard developmental toxicology studies should include not only tabulation of early losses (miscarriage and resorption) but a characterization of their morphology or reason for loss. This would involve the examination ofconceptuses before their in utero death or, in the case of humans, collecting sonographic and fetal autopsy data. An understanding of why a conceptus died would surely enhance our ability to comprehend mechanisms of developmental toxicity.

**Cardiovascular Function**

**Acute effects.** Cardioactive drugs can affect cardiac function of the fetus, especially in the third trimester, but it is not yet clear what, if any, long-range effects may result. Studies to collect this information should be supported. Some suggestive lines of evidence for functional impairment of cardiac function from fetal exposure include four that we mention here. First, cortisol inhibits cardiac myocyte replication and simulates the postnatal growth pattern (hypertrophy) of the heart (10). Second, in rats, nicotine affects sinoatrial reactivity to hypoxia without impairing cardiac conduction per se. This possibly explains the increased vulnerability of infants of mothers who smoke to sudden infant death syndrome (11). Third, thyroid status has been linked to muscle development. Thyroid hormone is required for proper development of the adult phenotype of myosin heavy chain of muscle (12). Although the experiment in rats was conducted on skeletal muscle, it may apply to cardiac muscle as well. Fourth, maternal lupus erythematosus is associated with fetal heart block; however, the biological basis for this observation remains obscure (13).

The role of the adrenals and kidneys, through their control of fetal blood pressure, in affecting development (e.g., weight and hemodynamics) is being explored (14), but long-term effects are largely unexplored. Cardiomyopathy may be genetic, infectious, or consequent to structural defects. Whether it might also be consequent to chemical exposure is unknown.

**Delayed effects.** We reviewed with interest the programming hypothesis that early changes lead to later effects (2). Low birth weight has been associated with an increased risk of developing hypertension, coronary artery disease, and diabetes—but why? The principal gap in knowledge is uncertainty about the etiologies and mechanisms of intrauterine growth restriction (IUGR). Morphological and functional studies of the placenta are underutilized in tackling the problem of IUGR. Early protein deprivation also appears to have long-term effects (1), but we need to understand more about basic mechanisms to generate better hypotheses. Maternal birth weight correlates with her infant’s birth weight (2)—but again, why? Certainly, we need a better understanding of possible links between lifestyle factors and cardiovascular effects (e.g., smoking and fetal cardiac myohyperplasia (15) or possible liability to later cardiovascular disease; cocaine exposure and possible liability to later cardiovascular disease).

We must distinguish between prematurity and IUGR because the mechanisms involved are quite different. There should also be differentiation between IUGR with and without postnatal catch-up growth because the former is likely to represent interference with late gestational nutrition, whereas the latter may stem from early gestational insult. Assessment of prenatal and postnatal growth should include weight, length (height), and head circumference as a minimum. More extensive growth profiling of human fetuses, including limb and visceral measurements, has shown that reasonably distinct patterns of growth aberration can be correlated with etiologic factors (16).

**Endocrine Function**

**Endocrine Structure**

To the best of our knowledge, structural defects of the endocrine glands (e.g., agenesis of any gland, annular pancreas, pancreatic neodiblastosis, lingual thyroid, and aberrant adrenal nodules) have not been related to environmental exposures. Goiter, which does have environmental exposure antecedents, is viewed as a functional defect.
prenatal or postnatal environmental exposure is uncertain.

Parathyroid. Calcification abnormalities are difficult to interpret as an endocrinological function, as they may involve mechanisms other than parathyroid function. We know of no suggestion of environmental induction of abnormal parathyroid function, but we did not fully explore the issue.

Thymus, pineal, and gonads. We did not discuss the function of these organs, or their discussion was deferred to other workshop sessions.

Conclusions

Many questions remain as to how early in gestation the various endocrine systems are active and important to the developmental process. The fetal window of vulnerability to endocrine dysfunction appears to be primarily the third trimester, but the second trimester is undoubtedly also important. Damage from first-trimester exposure is more problematic. Endocrine effects from environmental exposure could occur at any postnatal age, and although a number of such effects may be reversible, others may be permanent.

Pharmacological/chemical disruption of endocrine function is possible, but the full range of possibility has yet to be explored. Are effects only during exposure? What is the potential for recovery? Are there long-range effects? Are there permanent effects (e.g., on brain development or function; or on immune or reproductive function)? Screening for endocrine disruptors should include assessment of prenatal development. Diurnal and post cibum variation in hormone levels can complicate the collection and interpretation of data.

High-priority targets for research should include: a) thyroid, which is affected by environmental exposures (e.g., polychlorinated biphenyls); b) pancreas, especially β-cell function and its interaction with nutrition; c) adrenal stress response and cortisol production; and d) pituitary and the neuroendocrine axis.

We considered the appropriateness of various animal models for studying endocrine effects. For thyroid, commonly used animal models should be quite useful. For pancreatic function, rats are not appropriate as animal models because they can regenerate β-cells. For other hormones, there is insufficient information to comment, and although it was noted that steroids are teratogenic in certain strains of laboratory animals, similar patterns of teratogenicity have not been confirmed in humans.

We expressed a number of qualifications about extrapolating from laboratory animal data to the human situation. We agreed that uniformity of effects across species carries greater weight for predicting human effects than does abnormality occurring in only one species. When comparing studies in different species, it is essential to match for the comparable stage of development in each species. Animal models should be chosen for as much pharmacokinetic and metabolic similarity to humans as possible.

We noted that there are distinctions to be made among statistical, biological, and social significance of a finding of developmental toxicity. Although the maxim that an ounce of prevention is worth a pound of cure is undoubtedly true, in setting priorities for regulatory action, greater weight should be placed on those agents with proven developmental toxicants; this was thought to apply more certainly for structural aberrations but also for functional aberrations. Rather, the possibility is greater that there are undetected low-level toxicants and agents with delayed effects. We urge support of long-range studies linking relatively uncommon and/or delayed outcomes to exposure; these studies will be important to our understanding of the particular vulnerability of children to developmental toxicants.

References and Notes

1. Hoet JJ, Oseme S, Reutens B. Influences of pre- and postnatal nutritional exposures on vascular/endocrine systems in animals. Environ Health Perspect 106(suppl 3):563-568 (2000).

2. Osmond C, Barker DJP. Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. Environ Health Perspect 108(suppl 3):545-550 (2000).

3. Sadler TW. Susceptible periods during embryogenesis of the heart and endocrine glands. Environ Health Perspect 106(suppl 3):555-561 (2000).

4. Biddle FG, Fraser FC. Maternal and cytoplasmic effects in experimental teratology. In: Handbook of Teratology, Vol 3 (Wilson JG, Fraser FC, eds). New York:Plenum Press, 1977:3-33.

5. Ingram JI, Rodier PM. Valproic acid alters expression of t-hox at 1 in rat embryos: a mechanism of teratogenesis? [Abstract]. Teratology 57:101 (1998).

6. Robert E. Personal communication.

7. Barr M. Unpublished observations.

8. Clark EB. Mechanisms in the pathogenesis of congenital heart defects. In The Genetics of Cardiovascular Disease (Feinberg MEM, Moller JH, eds). Boston:Martinus-Nijoff, 1987:3-11.

9. Ference C, Loffredo CA, Correa-Villasenor A, Wilson PD. Risk factor analyses: a synthesis. In: Genetic and Environmental Risk Factors of Major Cardiovascular Malformations. The Baltimore-Washington Infant Study 1981-1989 (Ference C, Loffredo CA, Correa-Villasenor A, Wilson PD, eds). Aromonk, NY:Future Publishing Co., 1997:359-382.

10. Rudolph AM, Roman C, Gourlay M. Perinatal myocardial DNA and protein changes in the lamb: effect of cortisol in the fetus. Pediatr Res 48:141-146 (1999).

11. Slothkin TA, Saleh JI, McCook EC, Seidler FJ. Impaired cardiac function during postnatal hypoxia in rats exposed to nicotine prenatally. Implications for perinatal morbidity and mortality, and for sudden infant death syndrome. Teratology 55:177-184 (1997).

12. Adams GR, McCue SA, Zeng M, Baldwin KM. Time course of myosin heavy chain transitions in neonatal rats: importance of innervation and thyroid state. Am J Physiol 276:H954-H961 (1999).

13. Schaller JG. Neonatal lupus. In: Nelson Textbook of Pediatrics, 15th ed (Behrman RE, Kliegman RM, Arvin AM, eds). Philadelphia:W.B. Saunders Co., 1996:676.

14. Barr M. Angiotensin-converting enzyme inhibitor fetoathy. In: Handbook of Experimental Pharmacology: Drug Toxicity in Embryonic Development II (Kawasaki JS, Gudeon GP, eds). New York:Springer-Verlag, 1996:295-294.

15. Barr M. Effect of maternal smoking on fetal lung and heart weight [Abstract]. Teratology 59:137 (1999).

16. Barr M. Growth as a manifestation of teratogenesis: lessons from human fetal pathology. Reprod Toxicol 11:583-587 (1997).

17. Kliegman RM, Behrman E. Infants of diabetic mothers. In: Nelson Textbook of Pediatrics, 13th ed (Behrman RE, Vaughan VC, Nelson WE, eds). Philadelphia:W.B. Saunders Co., 1997:419.

18. Gailland DA, Lallemand AV, Moret HH, Vesseaux-Colette BJ, Paradis PH. Fetal adrenal development during the second trimester of gestation. Pediatr Pathol 10:335-350 (1990).

19. Barr M. Correlates of prenatal viscerocegaly. Am J Med Genet 79:249-252 (1998).